Willemijn J. Scholten
YOU?
Author Swipe
View article: Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial Open
View article: Different features of acute myeloid leukemia stem cell quantification in intensively treated patients
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients Open
In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognosti…
View article: CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents Open
View article: The role of the primitive marker <scp>CD133</scp> in <scp>CD34</scp>‐negative acute myeloid leukemia for the detection of leukemia stem cells
The role of the primitive marker <span>CD133</span> in <span>CD34</span>‐negative acute myeloid leukemia for the detection of leukemia stem cells Open
The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38− LSC load is associated with poor prognosis. I…
View article: Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia Open
View article: Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML Open
Acute myeloid leukemia (AML) is a heterogeneous disease both in terms of genetics and clinical outcome.1 Patients can be subdivided into 3 risk groups using the European LeukemiaNet (ELN) prognostic risk classification with significantly d…
View article: P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML
P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML Open
Background: Measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) in bone marrow (BM) after two cycles of high-dose induction chemotherapy has strong prognostic value and predicts relapse when applied to patient…
View article: P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY. Open
Background: Measurable residual disease (MRD) is currently implemented to guide consolidation treatment in intermediate-risk AML. Optimization of MRD results is therefore crucial for clinical decision making. MRD can be detected by multipa…
View article: Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial
Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial Open
Contains fulltext : 293618.pdf (Publisher’s version ) (Open Access)
View article: Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting Open
Summary Leukaemic stem cells (LSC) have been experimentally defined as the leukaemia‐propagating population and are thought to be the cellular reservoir of relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements are warranted…
View article: Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia Open
Response criteria in acute myeloid leukemia (AML) has recently been re-established, with morphologic examination utilized to determine whether patients have achieved complete remission (CR). Approximately half of the adult patients who ent…
View article: Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia Open
Response criteria in acute myeloid leukemia (AML) has recently been re-established, with morphologic examination utilized to determine whether patients have achieved complete remission (CR). Approximately half of the adult patients who ent…